Aims: Inflammation has been postulated to modify the platelet response to aspirin treatment, thereby causing high on-treatment residual platelet reactivity (HRPR). Both high levels of inflammatory markers and HRPR have been linked to adverse cardiovascular events. We aimed to study the impact of inflammation on residual arachidonic acid (AA)-inducible platelet reactivity. Methods: In 288 patients receiving dual antiplatelet therapy, residual AA-inducible platelet reactivity was assessed using light transmission aggregometry (LTA), the VerifyNow assay, multiple electrode aggregometry (MEA) and the Impact-R. The levels of urinary 11-dehydro-thromboxane B2 (D-TXB2), serum thromboxane B2 (TXB2), interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP) were determined using immunoassays. Results: The IL-6 level was found to be an independent predictor of platelet reactivity as determined according to LTA and D-TXB2 using a multiple linear regression analysis. Accordingly, patients with supramedian IL-6 levels exhibited significantly higher platelet reactivity than patients with inframedian IL-6 levels when determined according to LTA and D-TXB2 (both p ≤ 0.02). High IL-6 levels were associated with a 3.6-fold (95%CI 2.1-6.4) increased risk of HRPR, as defined according to D-TXB2, and a 3.4-fold (95%CI 1.4-8.3) increased risk of HRPR, as defined according to MEA. The HsCRP level was found to be an independent predictor of platelet reactivity when determined according to LTA, D-TXB2, the Impact-R and TXB2 using a multiple linear regression analysis. High hsCRP levels were associated with a 3.6-fold (95%CI 1.3-10) increased risk of HRPR, as defined according to LTA, and a 2.5-fold (95%CI 1.3-4.6) increased risk of HRPR, as defined according to TXB2. Conclusions: Increased levels of inflammatory markers are independently associated with residual AA-inducible platelet reactivity in patients receiving dual antiplatelet treatment. 
Introduction
Aspirin is routinely prescribed for the primary and secondary prevention of cardiovascular disease 1, 2) . Through the acetylation of serine 529, aspirin irreversibly inhibits platelet cyclooxygenase (COX)-1 and consequently averts platelet thromboxane A2 biosynthesis 3) . In large secondary prevention trials, low-dose aspirin has been found to reduce the risk of stroke, myocardial infarction and cardiovascular death by 20% in high-risk patients 4, 5) . However, a considerable number of patients continue to experience athero-thrombotic events despite receiving aspirin therapy 6, 7) . Platelet reactivity during antiplatelet treatment can be assessed using various test systems 8) and exhibits great interindividual variability in all assays. In previous studies, the results obtained with different methods yielded only limited correlations and high heterogeneity concerning the classification of patients as aspirin responders or nonresponders [9] [10] [11] . Several factors have been proposed to influence the antiplatelet effects of aspirin 12, 13) . In addition to pharmacological interactions, diabetes, hyperlipidemia, high platelet turnover, smoking and oxidative stress can significantly impair aspirin-mediated platelet inhibition 12, [14] [15] [16] [17] [18] . Moreover, inflammation has been postulated to modify the platelet response to aspirin treatment, thereby causing high on-treatment residual platelet reactivity (HRPR) 13) . Both high levels of inflammatory markers and HRPR have been linked to adverse cardiovascular events [19] [20] [21] [22] [23] [24] [25] [26] . However, it remains unclear whether and to what extent the antiplatelet effects of aspirin are affected by systemic inflammation 27) . Since diverse test systems cover different aspects of platelet activation, inflammatory processes may influence the results of one method more pronounced than those of other assays. We therefore aimed to study the impact of inflammation on various assays measuring residual arachidonic acid (AA)-inducible platelet reactivity in patients receiving dual antiplatelet therapy.
Methods

Patients
Residual AA-inducible platelet reactivity was determined in 288 patients with peripheral, coronary or carotid artery disease who underwent percutaneous intervention with endovascular stent implantation. The clinical, laboratory and procedural characteristics of the patients are shown in Table 1 .
Most patients (n=261; 90.6%) received daily aspirin (100 mg/d) for at least two weeks prior to percutaneous intervention. Those who were not treated with continuous aspirin therapy (n = 27; 9.4%) received a loading dose of 250 mg of aspirin intravenously prior to intervention followed by a daily dose of 100 mg of aspirin. Except 62 patients (21.5%) who received clopidogrel maintenance therapy, all patients received a loading dose of 300 (n=148, 51.4%) or 600 mg (n = 78, 27.1%) of clopidogrel prior to intervention followed by a daily dose of 75 mg of clopidogrel. The exclusion criteria were known intolerance to acetylsalicylic acid or clopidogrel (allergic reactions, gastrointestinal bleeding), therapy with vitamin K antagonists (warfarin, phenprocoumon, acenocoumarol), treat- are typically lower than 6%.
The HsCRP level was measured using fully automated particle enhanced immunonephelometry (N high-sensitivity CRP, Dade Behring, Marburg, Germany) on a Behring nephelometer II (BN Systems, Orchard Park, NY) 28) .
Measurement of the Urinary 11-Dehydro-Thromboxane B2 (D-TXB2) Level
The urine samples were thawed and assayed using a commercially available immunoassay, according to the manufacturer's instructions (Cayman Chemical, Ann Arbor, Michigan). The assay has inter-and intraassay coefficients of variation of 12.1% and 10%, respectively 22, 23) .
Measurement of the Serum Thromboxane B2 (TXB2) Level
The serum samples were thawed and assayed using a commercially available immunoassay, according to the manufacturer's instructions (Cayman Chemical, Ann Arbor, Michigan). The reported intra-and inter-assay coefficients of variation are typically lower than 10% 29) .
Light Transmission Aggregometry (LTA)
LTA was performed on the APACT 4S Plus aggregometer (LABiTec, Ahrensburg, Germany), as previously described 9) . Citrate-anticoagulated whole blood was centrifuged at 150×g for 10 minutes at room temperature to obtain platelet rich plasma (PRP). Platelet poor plasma (PPP) was obtained from the remaining specimens using recentrifugation at 2000×g for 10 minutes. The platelet counts were not adjusted, as the median platelet count was 208 G/L (interquartile range: 174 -249 G/L) 30, 31) . The baseline optical density was set using PPP. Aggregation was performed using arachidonic acid (AA; Rolf Greiner BioChemica, Flacht, Germany) at a final concentration of 0.5 mg/mL, and the optical density changes were recorded photoelectrically for 10 minutes as the platelets began to aggregate. The maximal aggregation response was registered and used to differentiate between patients with and without HRPR.
VerifyNow Aspirin Assay
The VN system (Accumetrics, San Diego, CA, USA) is a turbidimetric-based optical detection system that measures platelet-induced aggregation as an increase in light transmittance in whole blood 9) . The assay device contains reagents based on microbead agglutination technology, in particular a lyophilized preparation consisting of human fibrinogen-coated beads, platelet agonists, preservative and buffer. ment with prasugrel, ticagrelor, ticlopidine, dipyridamol or nonsteroidal anti-inflammatory drugs, a family or personal history of bleeding disorders, malignant paraproteinemia, myeloproliferative disorders or heparin-induced thrombocytopenia, severe hepatic failure, known qualitative defects in the thrombocyte function, major surgical procedures within one week before enrollment, a platelet count of ＜100.000 or ＞450.000/μL and a hematocrit level of ＜30%.
The study protocol was approved by the Ethics Committee of the Medical University of Vienna in accordance with the Declaration of Helsinki, and written informed consent was obtained from all study participants.
Urine and Blood Sampling
First morning urine specimens were collected from all patients the day after percutaneous intervention prior to blood sampling. All urine samples were stored at −80 ℃ until the analysis. Blood was drawn from the antecubital vein using clean venipuncture with a 21-gauge butterfly needle (0.8×19 mm; Greiner Bio-One, Kremsmünster, Austria) at the same time point 24 hours after percutaneous intervention. To prevent any procedural deviations, all blood samples were obtained by the same physician applying a light tourniquet. The tourniquet was immediately released, and the samples were mixed adequately by gently inverting the tubes. The initial 3 mL of blood was discarded to reduce procedurally induced platelet activation, and the blood was drawn into a 3.8% sodium citrate Vacuette tube (Greiner Bio-One; 9 parts of whole blood, 1 part of sodium citrate 0.129 M/L) for light transmission aggregometry (LTA), into a 3.2% sodium citrate Vacuette tube (Greiner Bio-One; 9 parts of whole blood, 1 part of sodium citrate 0.109 M/L) for the VerifyNow aspirin assay and into a Vacuette tube containing lithium heparin (18 IU/mL) for multiple electrode aggregometry (MEA) and the Impact-R. The time interval between blood sampling and testing was at least one hour and did not exceed three hours. To prevent investigator-related variation in the results, each of the different tests was performed by one corresponding operator who was blinded to the results obtained by the other operators.
Measurement of the Interleukin-6 (IL-6) and HighSensitivity C-reactive Protein (hsCRP) Levels
The IL-6 antigen levels were measured using the Elecsys IL-6 kit (Roche Diagnostics) on the ECL technology based COBAS e411 (Roche Diagnostics). The lower detection limit of this system is 1.5 pg/mL. The reported intra-and inter-assay coefficients of variation tube resulting in reduced platelet adhesion to the well, as reflected by reduced SC. This reduction was attenuated in the samples obtained from the patients treated with and responding well to aspirin, while a full reduction was observed in the patients with residual AAinducible platelet aggregation despite aspirin treatment.
Statistical Analysis
Continuous data are expressed as the mean±SD or median (interquartile range), and categorical data are expressed as the count (percentage). Differences between groups were evaluated using the non-parametric Wilcoxon rank-sum test or the chi-square test, as appropriate. Multiple linear regression analyses were used to analyze the associations between the inflammatory markers and the platelet function test results. As the inflammatory markers had skewed distributions, they were log-transformed for the regression analysis. Residual plots and the assumption of homogeneity of variance were examined in all of the analyses. In several platelet function tests, the variability in the differences between the observed and predicted values was greater for higher values and was eliminated by performing multiple regression analyses of the logtransformed response data. Data for all transformed variables were approximately normally distributed. Literature-based cutoff values were used to define HRPR for the following platelet activation markers: urinary D-TXB2 22, 23) , LTA 21) , the VerifyNow aspirin assay 24, 25) , MEA 33) and the Impact-R 32) . The corresponding cutoff values were a maximal aggregation of ≥ 20% for LTA, a urinary D-TXB2 concentration of ≥ 67.9 ng/mmol creatinine, ARU of ≥ 550 for the VN, AU of ≥ 30 for the MEA and a surface coverage of ≤ 3.4% for the Impact-R 21-25, 32, 33) . With respect to serum TXB2, the concentrations in the fourth quartile were considered to reflect HRPR. The corresponding cutoff value was a serum TXB2 concentration of ≥ 617 pg/mL. A multivariable logistic regression analysis was used to assess the association between the inflammatory markers and the presence of HRPR, as defined in the platelet function tests. Covariates for adjustment in the linear and logistic multivariable models were selected on the basis of the univariate analyses (p-value ≤ 0.1) and included age, sex, hypertension, hyperlipidemia, diabetes, smoking and the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta-blockers, proton pump inhibitors and/or calcium channel blockers. In addition, the analyses were adjusted for the platelet and white blood cell (WBC) counts. Five subjects with an IL-6 level above 100 pg/mL were excluded in an exploratory analysis, as this finding can indicate the Citrate-anticoagulated whole blood was automatically dispensed from the blood collection tube into the assay device by the instrument. AA was incorporated into the assay channel to induce platelet activation, and the light transmittance increased as activated platelets bound together and aggregated fibrinogen-coated beads. The instrument measured this change in optical signal and reported the results in Aspirin Reaction Units (ARU). In this assay, a higher ARU value reflects a greater degree of AA-inducible platelet reactivity.
Multiple Electrode Platelet Aggregometry (MEA)
Whole blood impedance aggregometry was performed using the Multiplate analyzer (Verum Diagnostica, Munich, Germany), as previously described 9) . One Multiplate test cell contains two independent sensor units, one of which consists of two silver-coated highly conductive copper wires with a length of 3.2 mm. Following dilution (1:2 with 0.9% NaCl solution) of heparin-anticoagulated whole blood and stirring in the test cuvettes for three minutes at 37℃, AA (Verum Diagnostica, Munich, Germany, final concentration of 0.5 mM) was added, and the aggregation was continuously recorded for five minutes. The adhesion of activated platelets to the electrodes led to an increase in impedance, which was detected for each sensor unit separately and transformed into aggregation units (AUs) plotted against time.
Impact-R Test
The Impact-R (Matis Medical, Beersel, Belgium) is a commercially available version of a cone and plate analyzer 9, 32) . In brief, 130 μL of lithium heparin-anticoagulated whole blood was placed on the polystyrene plate. Shear stress was immediately applied (2050 s-1) using a acrylonitrile-butadiene-styrene cone. The plates were then washed with tap water and stained with May-Grünwald solution following the manufacturer's instructions. The samples were analyzed using an inverted light microscope connected to an image analyzer (Galai, Migdal Haemek, Israel). As in previous reports, only platelet adhesion determined by examining the percentage of total area covered with platelets (surface coverage, SC %) was used for the statistical analyses 32) . Seven images were collected from each run and the medians of these values were calculated by the analyzing system.
In the AA-response test, the whole blood samples were preincubated with 275 μM AA (DiaMed, Cressier, Switzerland) for one minute under gentle mixing (10 rpm) prior to the Impact-R test. This led to platelet activation and microaggregate formation in the Covariates for the multiple linear regression analyses were chosen according to the results of the univariate analyses, as presented in supplementary Table 1-8. The results of the multiple linear regression analyses of the levels of IL-6 and hsCRP are presented in Table 2 . The results of the multiple linear regression presence of acute inflammatory disease. The results were modestly stronger after excluding these individuals, yet the statistical significance remained largely the same. Spearman correlation coefficients were used to assess the correlations between the levels of IL-6 and hsCRP and between the serum TXB2 level and the other platelet reactivity test results. The results of all participants are reported. The statistical analysis was performed using the SAS version 9.2 software program (SAS Institute, Cary, NC, USA). A two-sided p value of ＜0.05 was considered to be statistically significant.
Results
The baseline patient characteristics and results of the laboratory tests are presented in Table 1 . Twentythree patients (8%) underwent emergency intervention. As expected, the patients treated with emergency intervention exhibited higher hsCRP levels than the patients who underwent elective angioplasty (p = 0.005). In contrast, the IL-6 levels were similar between the patients treated with elective and emergency intervention (p = 0.9). Among the overall study population, the levels of IL-6 and hsCRP were significantly correlated with each other (r = 0.56; p＜0.001).
Effects of Inflammation on Platelet Reactivity Tests
The patients were dichotomized according to the median Il-6 (≤ 15.9 pg/mL or ＞15.9 pg/mL) and hsCRP (≤ 0.78 mg/dL or ＞0.78 mg/dL) levels in order to compare the results of the platelet function tests between patients with a high and low inflammatory status. Patients with supramedian IL-6 levels exhibited significantly higher platelet reactivity than patients with inframedian IL-6 levels, as determined according to LTA (maximal aggregation: 4. Fig. 1A,  B) . No such differences were observed when residual platelet reactivity was measured using the VerifyNow aspirin assay, MEA, the Impact-R or serum TXB2 (Fig. 1 C, D, E, F) . The individual values of interleukin-6 compared to LTA and D-TXB2 are depicted in Fig. 2A and B 
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MEA and the Impact-R, while the WBC count was found to be independently associated with platelet reactivity according to the VerifyNow assay and MEA.
Impact of Inflammatory Markers on HRPR
The proportions of patients exhibiting HRPR in each test system are presented in Table 3 . In the univariate analyses, the number of patients with HRPR differed significantly between those with high and low Il-6 levels when D-TXB2, MEA and serum TXB2
analyses of IL-6, hsCRP and all covariates are presented in supplementary Table 9 and 10. The IL-6 level was found to be an independent predictor of platelet reactivity according to LTA (p = 0.01) and D-TXB2 (p＜0.0001). The HsCRP level was found to be an independent predictor of platelet reactivity according to LTA (p = 0.0004), D-TXB2 (p = 0.02), the Impact-R (p = 0.02) and serum TXB2 (p = 0.003). The platelet count was found to be independently associated with platelet reactivity according to the serum TXB2 were used to quantify platelet reactivity. In the multivariate logistic regression analysis, a high hsCRP level was associated with a 3.6-fold (95%CI 1.3-10) increased risk of HRPR, as defined according to LTA, and a 2.5-fold (95%CI 1.3-4.6) increased risk of HRPR, as defined according to serum TXB2. No effects of hsCRP were observed in the other assays ( Table 3) .
The level of serum TXB2 was significantly correlated with the level of urinary D-TXB2 and with were used to quantify platelet reactivity. In the multivariate logistic regression analysis, a high IL-6 level was associated with a 3.6-fold (95%CI 2.1-6.4) increased risk of HRPR, as defined according to D-TXB2, and a 3.4-fold (95%CI 1.4-8.3) increased risk of HRPR, as defined according to MEA. No effects of IL-6 were observed in the other assays ( Table 3) .
In the univariate analyses, the number of patients with HRPR differed significantly between those with high and low hsCRP levels when LTA, MEA and compared to that observed in the patients with low IL-6 levels. The use of the median hsCRP level as a cutoff value for the inflammatory status yielded similar results. Furthermore, a high IL-6 level was found to be an independent predictor of increased platelet reactivity, as measured according to LTA and D-TXB2, and was independently associated with a significantly increased risk of HRPR, as defined according to D-TXB2 and MEA. A high hsCRP level was found to be an independent predictor of platelet reactivity MEA ( Table 4) .
Supplementary
Discussion
In our study, we assessed the impact of inflammation on various laboratory assays measuring residual AA-inducible platelet reactivity in patients receiving dual antiplatelet treatment. The patients with high IL-6 levels exhibited significantly higher platelet reactivity, as determined according to LTA and D-TXB2, 22, 23) . In our cohort, the strongest association between inflammatory markers and residual platelet reactivity was observed for urinary D-TXB2, suggesting a potential role of additional aspirin-insensitive thromboxane generation. In detail, thromboxane derived from non-platelet sources, generated via an increased COX-2 expression in leukocytes or the according to LTA, D-TXB2, the Impact-R and serum TXB2, and was independently associated with a significantly increased risk of HRPR, as assessed according to LTA and serum TXB2.
Supplementary
We used six different methods to estimate residual platelet reactivity. D-TXB2 is a degradation product of TXA2, which is excreted by the kidneys. The urinary concentration of D-TXB2 is considered to be indicative for the extent of TXA2 generation, and a high level of urinary D-TXB2 may mirror HRPR.
Supplementary Table 7.
Surface coverage (SC) % by the Impact-R in patients with and without age ≥ 75 years, male sex, hypertension, hypercholesterolemia, diabetes mellitus, active smoking, statin, angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), beta blocker, proton pump inhibitor, and calcium-channel blocker MEA measures residual platelet reactivity using impedance aggregometry. Recently, the presence of HRPR as assessed according to MEA was found to be independently associated with adverse cardiac events in 403 patients undergoing PCI 37) . We found a 3.4-fold increased risk of HRPR according to MEA in patients with a high IL-6 level.
The Impact-R can be considered as inverse aggregometry 32) . Data linking the results obtained from the Impact-R with clinical outcomes are scarce and conflicting. While Spectre et al. revealed a significantly lower rate of major adverse cardiovascular events (MACEs) six months after PCI in patients showing a good response to aspirin in the Impact-R 38) , the Impact-R was not able to discriminate between patients who did and did not experience atherothrombotic events one year post-PCI in a study by Breet et al. 26) . In our study, the hsCRP level was found to be an independent predictor of platelet reactivity measured using the Impact-R.
We assessed on-treatment platelet reactivity 24 hours after the percutaneous intervention. Therefore, the mean time span from loading to laboratory measurement was 36 hours, and previous studies have shown that the major antiplatelet effects of aspirin and clopidogrel have occurred after this time interval [39] [40] [41] . There are currently no commonly agreed thresholds for HRPR. We decided to base the cutoff values for HRPR on the findings of previous studies showing an association between HRPR and adverse clinical outcomes [21] [22] [23] [24] [25] 33) . Alternatively, the threshold for HRPR can be defined according to the change in platelet reactivity following the initiation of antiplatelet therapy 42) . This approach, however, requires an assessment of pretreatment platelet aggregation. Consequently, it is time-consuming, laborious and hardly feasible in routine clinical practice, as treatment is usually started without prior platelet function testing. In our study, the vast majority of patients received endothelium, may contribute to the observed association [34] [35] [36] . The weaker impact of inflammation on serum TXB2 also supports the assumption that extraplatelet sources play a role in the strong correlation between inflammation and urinary D-TXB2. LTA captures the increase of light transmittance through a sample following the addition of AA and thereby estimates the extent of residual platelet aggregation. The results of LTA have been linked to the occurrence of major adverse cardiovascular events in stable patients receiving aspirin therapy 21) and in patients receiving dual antiplatelet therapy undergoing elective percutaneous coronary intervention (PCI) 26) . In our study, patients with supramedian IL-6 or hsCRP levels exhibited significantly higher residual platelet reactivity according to LTA, indicating the effects of inflammation on the results of LTA. This assumption is strengthened by our finding that the IL-6 and hsCRP levels are independent predictors of platelet reactivity assessed according to LTA. However, maximal aggregation by LTA demonstrated a pronounced overlap between patients with supra-and inframedian IL-6 levels ( Fig. 2A) , and the rate of HRPR determined according to LTA did not differ significantly between the patient groups. Furthermore, we observed rather low aggregation levels and a low number of patients with HRPR by LTA, questioning the clinical relevance of these observations.
The VerifyNow aspirin assay is a rapid and fully standardized point-of-care device. Chen et al. reported an increased risk of adverse outcomes in stable patients with coronary artery disease who exhibited HRPR in the VerifyNow aspirin assay 24) . Moreover, patients with HRPR, as assessed according to the VerifyNow aspirin assay, exhibit a higher incidence of myonecrosis and atherothrombotic events following non-urgent PCI 25, 26) . In our study, the results of the VerifyNow aspirin assay were not significantly influenced by markers of inflammation. 37, 43) , whereas data on the influence of inflammatory markers on the antiplatelet effects of aspirin are scarce and limited to MEA 37, 44) . Müller et al. reported that the baseline levels of IL-6 and CRP correlate well chronic aspirin therapy; thus, obtaining pre-exposure measurements was not feasible.
Various studies have investigated the impact of inflammation on clopidogrel-mediated platelet inhibi- Supplementary Table 9 . Regression coefficients (B), standard deviations (SD) and p-values of multivariate regression analyses of log transformed interleukin-6 (logIL-6), age, sex, hypertension, hyperlipidemia, diabetes, smoking, use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers (ACE/ARB), beta-blockers, proton pump inhibitors (PPI), calcium-channel blockers (CCB), platelet count and white blood cell count (WBC) for light transmission aggregometry (LTA), urinary dehydro-thromboxane B2 (D-TXB2), the VerifyNow aspirin assay, multiple electrode aggregometry (MEA), the Impact-R and serum thromboxane B2 (TXB2) of MACE after PCI in that study 44) . Siller-Matula et al. also identified the CRP level to be an independent predictor of HRPR according to MEA 37) . These findings are in line with our results. As mentioned above, with AA-inducible platelet reactivity measured using MEA in patients with symptomatic coronary artery disease 44) . Moreover, both high baseline CRP and HRPR levels were found to be independent predictors Supplementary Table 10 . Regression coefficients (B), standard deviations (SD) and p-values of multivariate regression analyses of log transformed high sensitivity C-reactive protein (loghsCRP), age, sex, hypertension, hyperlipidemia, diabetes, smoking, use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers (ACE/ARB), beta-blockers, proton pump inhibitors (PPI), calcium-channel blockers (CCB), platelet count and white blood cell count (WBC) for light transmission aggregometry (LTA), urinary dehydro-thromboxane B2 (D-TXB2), the VerifyNow aspirin assay, multiple electrode aggregometry (MEA), the Impact-R and serum thromboxane B2 (TXB2) associated with an increased risk of both early and late stent thrombosis after PCI 46) . Our data indicate that HRPR may contribute to an increased rate of MACE in patients with inflammatory conditions.
Increased platelet turnover and a high platelet count during inflammatory processes may affect aspirin efficacy due to the more rapid regeneration of cyclooxygenase-1 activity. In our study, the platelet count was found to be independently associated with AA-inducible platelet reactivity measured using MEA and the Impact-R.
The limitations of our study comprise the lack of clinical outcome data and the correlational design. Furthermore, we did not measure platelet reactivity prior to percutaneous intervention and therefore could all previous studies linking inflammation to HRPR used only a single test system. Therefore, these studies could not reveal differences in the various methods regarding sensitivity to inflammatory stimuli. In contrast, we provided data for six laboratory assays used to measure the response to aspirin therapy. Indeed, we found a heterogeneous influence of inflammation on the various platelet function assays, which can be explained by the fact that each test system captures different aspects of platelet activation and is therefore sensitive to different influencing factors 45) . This finding is strengthened by the observation that different platelet function assays correlate poorly with each other [9] [10] [11] . Recently, high levels of IL-6 were found to be not make pre-and post-treatment comparisons. Moreover, the different angioplasty procedures may have influenced our results. The differences between the aggregation responses were rather small and overlapped to some extent. Due to the exploratory nature of the study design and analysis and the small sample size, this study should be considered a hypothesis generating study only.
Conclusion
Increased levels of inflammatory markers are independently associated with residual AA-inducible platelet reactivity in patients receiving dual antiplatelet treatment. These effects are most pronounced for D-TXB2, suggesting that additional aspirin-insensitive thromboxane generation might play a role for these findings.
